Inhibikase Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview

Inhibikase Therapeutics

08/08/2025 22:30

Inhibikase Therapeutics Inc IKT.OQ IKT.O is expected to  show no change in quarterly revenue when it reports  results on August 12 (estimated) for the period ending June 30 2025

​LSEG's mean analyst estimate for Inhibikase Therapeutics Inc is for a loss of 9 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Inhibikase Therapeutics Inc is $8.00, about 80.6% above its last closing price of $1.55

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATEÂŪ
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-0.10
-0.10
-0.17
Missed
-61.9
Dec. 31 2025
-0.09
-0.50
Missed
-476.9
Sep. 30 2024
-0.38
-0.37
-0.65
Missed
-75.7​
Jun. 30 2024
-0.67
-0.67
-0.66
Beat
1.5
​​Mar. 31 2024
-0.79
-0.79
-0.73
Beat
7.6
Dec. 31 2023
-0.86
-0.85
-0.64
Beat
24.7​
Sep. 30 2023
-1.12
-1.12
-0.86
Beat
23.2
Jun. 30 2023
-0.92
-0.92
-1.11
Missed
-20.7

This summary was machine generated August 8 at 21:30 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)